We are updating the design of this site. Learn more.
Show more
ClinicalTrials.gov Menu

The Role of Pro-angiogenic Immune Cells in Human Pregnancies

The recruitment status of this study is unknown. The completion date has passed and the status has not been verified in more than two years.
Verified August 2010 by Hillel Yaffe Medical Center.
Recruitment status was:  Recruiting
ClinicalTrials.gov Identifier:
First Posted: August 6, 2010
Last Update Posted: August 6, 2010
The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.
Information provided by:
Hillel Yaffe Medical Center
Identification of the presence of proangiogenic immune cells in normal human placentas may enable predication of some pregnancy disorders.

Condition Intervention
Fetal Growth Retardation Preeclampsia Other: Biological specimen

Study Type: Observational
Study Design: Observational Model: Case Control
Time Perspective: Retrospective

Resource links provided by NLM:

Further study details as provided by Hillel Yaffe Medical Center:

Primary Outcome Measures:
  • To find the angiogenic potential of proangiogenic immune cells derived from human placentas. [ Time Frame: Two years ]

Estimated Enrollment: 300
Study Start Date: August 2010
Estimated Study Completion Date: December 2011
Estimated Primary Completion Date: August 2011 (Final data collection date for primary outcome measure)
Groups/Cohorts Assigned Interventions
Placentas after delivery or abortion Other: Biological specimen
Biological specimen taken from placenta


Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.

Ages Eligible for Study:   Child, Adult, Senior
Sexes Eligible for Study:   Female
Accepts Healthy Volunteers:   Yes
Sampling Method:   Non-Probability Sample
Study Population
Placentas after delivery or abortion

Inclusion Criteria:

  • Placentas that have been delivered in the Medical Center

Exclusion Criteria:

  Contacts and Locations
Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT01177020

Contact: Elad Mei-Dan, MD 972-4-6304248 eladmei@yahoo.com

Hillel Yaffe Medical Center Recruiting
Hadera, Israel, 38100
Principal Investigator: Elad Meidan, MD         
Sponsors and Collaborators
Hillel Yaffe Medical Center
  More Information

Responsible Party: Elad Mei-Dan, MD, Hillel Yaffe Medical Center
ClinicalTrials.gov Identifier: NCT01177020     History of Changes
Other Study ID Numbers: HYMC1069A
First Submitted: May 12, 2010
First Posted: August 6, 2010
Last Update Posted: August 6, 2010
Last Verified: August 2010

Additional relevant MeSH terms:
Fetal Growth Retardation
Hypertension, Pregnancy-Induced
Pregnancy Complications
Fetal Diseases
Growth Disorders
Pathologic Processes